Change the DNA of your portfolio: growth opportunities through genomics

JThanks to DNA sequencing and the genomic revolution, we could be at the dawn of a whole new era of healthcare solutions that could extend and improve the quality of human life. Several key biotechnology companies are at the forefront of scientific developments that may change everything we know about healthcare.

In the next webcast, Change the DNA of your portfolio: growth opportunities through genomicsNicholas Grous, Associate Portfolio Manager, ARK Invest, and Simon Barnett, Research Analyst, ARK Invest, will provide an in-depth discussion on the companies driving change in targeted therapies, bioinformatics, CRISPR technology, and more.

More specifically, the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG) is an actively managed strategy that seeks long-term capital growth by investing in domestic and foreign equity securities of companies across multiple industries, including healthcare, information technology, materials, energy and consumer discretionary, which are relevant to the Genomic Revolution Fund’s investment theme.

According to ARK Invest, companies within ARKG are focused on extending and improving the quality of human and other life by integrating technological and scientific developments and advances in genomics into their business, and should benefit considerably. ARKG will focus on issuers in any sector or group of sectors within the healthcare sector, including issuers whose principal business activities are in the biotechnology sector. Companies held in ARKG can be technology leaders, enablers or recipients.

ARKG’s portfolio will consist of companies engaged in CRISPR technology, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology. Top holdings include: Exact Sciences $8.4, Ionis Pharmaceuticals 6.3%, Teladoc Health 5.5%, CRISPR Therapeutics 5.0% and Signify Health 4.3%.

“Genomic sequencing is changing the way biological information is collected, processed and applied. ARKG is focused on disruptive innovations that increase precision, restructure healthcare, agriculture, pharmaceuticals, and improve quality of life,” according to ARK Invest.

Financial advisors interested in learning more about growth opportunities in the biotech segment can register for the Wednesday, June 8 webcast here.

Learn more at

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button